SGMT · Sagimet Biosciences Inc.
Market Cap
$680.02M
Shares
62.16M
SGMT metrics
51 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$10.94
Market cap
$680.02M
Price action
19 metricsPrice change (1W)
+3.7%
Price change (30D)
+14.3%
Price change (3M)
+61.8%
Price change (6M)
+102.2%
Price change (YTD)
+84.8%
Price change (1Y)
+50.9%
Trailing year
Price change (5Y)
—
52-week high
$10.99
52-week low
$4.55
Change from 52-week high
-0.5%
Change from 52-week low
+140.4%
Annualized volatility
85.1%
Beta
2.0
RSI (14D)
68.1
Price vs SMA 50
+26.2%
Price vs SMA 200
+60.2%
Avg volume (3M)
1.24M
Relative volume
1.0
Average dollar volume
$10.24M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
62.16M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.7
reciprocal yield 37.7%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-6.9%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-05-12
Profitability
9 metricsGross margin
—
Operating margin
-1,537.0%
Trailing 12 months
Net margin
-1,393.8%
Gross profit (TTM)
—
Operating profit (TTM)
−$52.63M
Net income (TTM)
−$47.08M
Trailing 12 months
Diluted EPS (TTM)
$-1.29
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+65.0%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-18.4%
Return on assets
-17.9%
Debt / equity
—
Current ratio
45.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
45.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$240.13M
Latest balance sheet
Cash & equivalents
$165.90M
Total assets
$263.43M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$41.72M
Capital expenditures (TTM)
—
R&D (TTM)
$34.99M
SG&A (TTM)
—
Stock compensation (TTM)
$8.91M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
123
13F filer change QoQ
+35
Institutional ownership
83.2%
Short interest
3 metricsShort interest
18.9%
Latest settlement · 6.9 days to cover
Days to cover
6.9d
Short-squeeze score
74 / 100
Insider activity
2 metricsNet insider buying (90D)
−$4.51M
Insider-sentiment score
28 / 100
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1400118
CUSIP
786700104
13F (30d)
94 filings
94 filers
Visit website
Investor relations